Insulet Co. (NASDAQ:PODD) Shares Sold by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC decreased its stake in shares of Insulet Co. (NASDAQ:PODDFree Report) by 18.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,735 shares of the medical instruments supplier’s stock after selling 1,327 shares during the period. Exchange Traded Concepts LLC’s holdings in Insulet were worth $1,244,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in PODD. HighTower Advisors LLC boosted its holdings in shares of Insulet by 1.4% in the first quarter. HighTower Advisors LLC now owns 2,968 shares of the medical instruments supplier’s stock worth $948,000 after buying an additional 41 shares during the period. Moneta Group Investment Advisors LLC boosted its holdings in shares of Insulet by 7.7% in the second quarter. Moneta Group Investment Advisors LLC now owns 743 shares of the medical instruments supplier’s stock worth $214,000 after buying an additional 53 shares during the period. Capula Management Ltd boosted its holdings in shares of Insulet by 7.4% in the second quarter. Capula Management Ltd now owns 920 shares of the medical instruments supplier’s stock worth $265,000 after buying an additional 63 shares during the period. Fund Management at Engine No. 1 LLC lifted its position in shares of Insulet by 7.7% in the second quarter. Fund Management at Engine No. 1 LLC now owns 907 shares of the medical instruments supplier’s stock worth $262,000 after purchasing an additional 65 shares in the last quarter. Finally, Cresset Asset Management LLC lifted its position in shares of Insulet by 6.6% in the first quarter. Cresset Asset Management LLC now owns 1,102 shares of the medical instruments supplier’s stock worth $293,000 after purchasing an additional 68 shares in the last quarter.

Insiders Place Their Bets

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of Insulet stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the sale, the director now owns 2,567 shares in the company, valued at $418,215.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.90% of the company’s stock.

Insulet Trading Down 1.1 %

Shares of Insulet stock opened at $165.86 on Monday. The company’s fifty day simple moving average is $189.09 and its 200-day simple moving average is $179.58. The company has a market cap of $11.60 billion, a price-to-earnings ratio of 57.00, a PEG ratio of 3.16 and a beta of 0.98. The company has a current ratio of 3.51, a quick ratio of 2.62 and a debt-to-equity ratio of 1.86. Insulet Co. has a 1 year low of $125.82 and a 1 year high of $335.91.

Insulet (NASDAQ:PODDGet Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.73. The business had revenue of $509.80 million for the quarter, compared to the consensus estimate of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. Insulet’s quarterly revenue was up 37.9% on a year-over-year basis. During the same quarter last year, the company posted $0.55 earnings per share. As a group, sell-side analysts expect that Insulet Co. will post 3.08 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PODD. Morgan Stanley raised shares of Insulet from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $185.00 to $234.00 in a research report on Monday, December 4th. Stifel Nicolaus raised their price objective on shares of Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research report on Monday, February 5th. Robert W. Baird raised shares of Insulet from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $180.00 to $238.00 in a research report on Thursday, December 21st. JPMorgan Chase & Co. raised their price objective on shares of Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Finally, Piper Sandler cut their price objective on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $250.33.

View Our Latest Research Report on PODD

About Insulet

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Featured Stories

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.